CHARGED ALPHATMFrontier AI stock research

NTRA · NasdaqGS

Natera, Inc.

Diagnostics & Research · United States

USD 412.820.1% daily changeQuote 2026-09-28 · USD
Market cap (USD)
US$59.51B
Trailing P/E
—
Forward P/E
—
Quarterly revenue growth
37.7%
Trailing net margin
-7.1%
Indicated dividend yield
—

Snapshot 2026-09-28 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-05 (provider estimate, not issuer-confirmed).

Company background

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Company website

Q2 2026

Go beyond the headline.

Natera (NTRA): A 13.6% Revenue Beat - And That Is The Base Rate

Published 2026-08-07

Comparable businesses

NTRA peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricNTRANatera, Inc.Snapshot 2026-09-28Financial period: 2026-06-30AAgilent Technologies, Inc.Snapshot 2026-09-28Financial period: 2026-07-31ILMNIllumina, Inc.Snapshot 2026-09-28Financial period: 2026-06-28Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$59.51BUS$49.02BUS$40.92BUS$44.97Bn=2
Forward P/EProvider forward earnings estimate—25.73x44.39x35.06xn=2
EV / EBITDAEnterprise value / trailing EBITDA—24.57x36.48x30.52xn=2
Revenue growthLatest quarter vs prior-year quarter37.7%8.1%9.4%8.8%n=2
Operating marginLatest reported quarter-10.3%25.6%21.1%23.3%n=2
Free cash flow yieldTrailing cash flow / market cap0.2%2.2%1.9%2.1%n=2
Net debt / EBITDANet debt / trailing EBITDA—1.15x1.18x1.16xn=2
Debt / equityTotal debt / positive book equity0.13x0.56x0.89x0.73xn=2
Trailing P/ETrailing twelve-month earnings—34.36x50.47x42.41xn=2
Price / bookPrice / positive book equity per share32.55x6.66x14.42x10.54xn=2
EV / salesEnterprise value / trailing revenue21.65x6.93x9.37x8.15xn=2
Earnings growthLatest quarter vs prior-year quarter—8.5%-9.4%-0.5%n=2
Gross marginTrailing twelve months65.2%53.6%67.9%60.8%n=2
Net marginTrailing twelve months-7.1%19.5%18.3%18.9%n=2
Return on equityProvider trailing return; positive equity only-12.5%21.0%32.3%26.7%n=2
Free cash flow marginTrailing free cash flow / revenue3.8%14.4%17.7%16.1%n=2
Dividend yieldIndicated annual dividend / price—0.6%——
Earnings payoutProvider trailing dividend payout0.0%20.0%0.0%10.0%n=2
Current ratioCurrent assets / current liabilities3.00x2.05x1.80x1.92xn=2
BetaProvider historical market sensitivity1.531.241.471.35n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-09-28. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for NTRA

All available reporting periods
Q2 20262026-08-07

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.